Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Volcano Corp. completes secondary stock offering: Intravascular ultrasound (IVUS) device maker grosses $58.6 mil. in proceeds from secondary stock offering of 3.5 mil. common stock shares at $16.75 each Dec. 7. Separately, 4 mil. shares also were offered by selling shareholders. The firm intends to use around $26 mil. of the proceeds for sales and marketing initiatives and $11 mil. for R&D. The stock sale comes just six months after the Rancho Cordova, Calif., firm went public, netting $58.2 mil. from the June sale of about 7.8 mil. shares (1"The Gray Sheet" Sept. 4, 2006, p. 12). The firm reported third quarter sales of $27.8 mil., up 3% from 2005. Under a collaboration with core labs at Stanford University, Cardialysis and the Cardiovascular Research Foundation, also announced Dec. 7, Volcano will provide IVUS catheters free of charge for use in pivotal drug-eluting stent trials to advance understanding of stent thrombosis. FDA's Circulatory System Devices Panel met Dec. 7-8 to discuss DES-related thrombosis...
You may also be interested in...
Volcano Ready To Erupt? Vascular Imaging Start-Up Lures Big-Time Partners
Ultrasound catheter firm Volcano Corp. only went public in June, but it has already attracted noticeable interest from the top players in the device industry
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.